Maged Shenouda - 16 May 2025 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
Chief Financial Officer
Signature
/s/ Maged Shenouda
Issuer symbol
RLMD
Transactions as of
16 May 2025
Net transactions value
+$97,208
Form type
4
Filing time
20 May 2025, 18:03:12 UTC
Previous filing
11 Sep 2024
Next filing
30 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shenouda Maged Chief Financial Officer C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES /s/ Maged Shenouda 20 May 2025 0001658369

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLMD Common Stock Purchase $22,100 +50,000 +57% $0.4420 138,335 16 May 2025 Direct F1, F2
transaction RLMD Common Stock Purchase $43,686 +90,000 +65% $0.4854 228,335 19 May 2025 Direct F1, F3
transaction RLMD Common Stock Purchase $31,422 +60,000 +26% $0.5237 288,335 20 May 2025 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2 Purchase prices range from $0.4229 to $0.4674 per share, inclusive.
F3 Purchase prices range from $0.4493 to $0.4998 per share, inclusive.
F4 Purchase prices range from $0.4998 to $0.5396 per share, inclusive.